The Barcelona Institute for Global Health (ISGlobal) is a cutting-edge institution with capacity to address global public health challenges through research, translation and education, with 385 members from 31 different countries. ISGlobal has a broad research portfolio in communicable and non-communicable diseases with special attention to environmental health determinants. Research is organized in 9 different programs: Air Pollution and Urban Environment; Chagas, Parasitic and other Imported Diseases; Childhood and Environment; Climate and Health; Malaria, HIV & TB; Maternal, Child and Reproductive Health; Radiation; NCDs and Environment; Viral and Bacterial Infections. ISGlobal’s approach is multidisciplinary, ranging from the molecular to the population level and including disciplines across health sciences, life sciences, environmental, social, economic and climate sciences. ISGlobal is an affiliated institute to the University of Barcelona and to the University Pompeu Fabra.
Main roles in the project
ISGlobal will be responsible for the economic-oriented WPs in this project. The multidisciplinary team is composed by: Elisa Sicuri, Maria Jesús Pinzaso, Celine Aerts (ISGlobal), Paula Sartor (Norwest National University of Argentina), Hector Freilij (Hospital de Niños Ricardo Gutiérrez, Buenos Aires), Emilio Malchiodi (University of Buenos Aires). The team will estimate the potential demand for the CRUZIVAX vaccine candidate and the quality of life associated with Chagas disease in both endemic (Chaco, Argentina) and non-endemic areas (Barcelona, Spain). The team will also estimate life-long cost-of-illness associated with Chagas disease through analysing the use of healthcare resources (and relative costs) of Chagas disease patients in Barcelona. This estimate represents the potential savings to the health system that may arise from the CRUZIVAX Chagas disease vaccine candidate implementation.
Contact: Dr Elisa Sicuri
This project has received funding from the European Union’s Horizon 2020 research and innovationprogramme under grant agreement No 815418.